Onureg (Azacitidine) Patent Expiration, LOE Window & CMS Spending

Onureg (Azacitidine) by Bristol Myers Squibb: FDA Orange Book LOE 2030-06-03, 0 AB generics, $102.7M 2024 CMS Part D & Medicaid spend, and 4 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorBristol Myers Squibb
FDA Application & PathwayN214120 (NDA)
Exclusivity / Cliff HorizonNear-Term Cliff (2028-2030)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2030-06-03
Orange Book Patents (*PED Extensions)3 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$102.7M
2024 Medicare Part D Spend$85.9M
2024 Medicaid Spend$16.8M
Reported Wholesale Price Change (CA SB 17)4 WAC filings (max 20.4% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Bristol Myers Squibb across sibling Meru public-data platforms.